Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions

Children's Oncology Group9,350 enrolled

Overview

This laboratory study is looking at genes in participants with neuroblastoma or noncancerous conditions. Identifying genes related to cancer may help in the study of cancer. It may also help doctors predict who is at risk of developing neuroblastoma.

OBJECTIVES: I. Perform a whole genome scan for association of neuroblastoma with single nucleotide polymorphisms (SNP) and SNP haplotypes. II. Identify true disease-associated SNP alleles using a customized genotyping platform enriched for haplotype analyses in an independent sample set. III. Validate disease-associated SNP alleles and haplotypes in a final independent sample set. IV. Identify neuroblastoma predisposition genes. OUTLINE: This is a multicenter study. Participants are stratified according to presence of high-risk disease (yes vs no) and MYCN amplification (yes vs no). DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition. Patients do not receive the results of the genetic testing. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the Children's Oncology Group.

Study Type

OBSERVATIONAL

Enrollment

9,350

Conditions

Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma Recurrent Neuroblastoma Regional Neuroblastoma Stage 4 Neuroblastoma

Interventions

Laboratory Biomarker AnalysisOTHER

Correlative studies

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patient: * Diagnosis of neuroblastoma * Banked constitutional and genomic DNA within COG-ANBL00B1 Neuroblastoma Biology protocol or another COG Biology Protocol * At least 1.0 ?g of DNA available * Control (age, race, and gender-matched): * No diagnosis of cancer * May have other conditions, including any of the following: * Asthma * Inflammatory bowel disease * Attention-deficit disorder * Obesity

Locations (2)

University of Mississippi Medical Center

Jackson, Mississippi, United States

Childrens Oncology Group

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Neuroblastoma predisposition genes

Time frame: Up to 4 years

Single nucleotide polymorphism (SNP) allele disease association

Time frame: Up to 4 years

SNP haplotype disease association

Time frame: Up to 4 years

Validation of SNP allele and haplotype disease association

Time frame: Up to 4 years

SNP association with phenotypic subsets (i.e., high-risk vs no high-risk disease; MYCN amplification vs no MYCN amplification)

Time frame: Up to 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.